文献速递淋巴瘤

生物类似药CT-P10与利妥昔单抗治疗初治低肿瘤负荷滤泡性淋巴瘤的疗效、药代动力学及安全性比较:一项随机、双盲、平行组、3期试验

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.
PubMed 文献 · Lancet Haematol · 2018-01-01

这项正在进行的随机、双盲、平行组、活性对照3期试验将258例初治II-IV期低肿瘤负荷滤泡性淋巴瘤患者按1:1随机分配至CT-P10组(130例)或利妥昔单抗组(128例),主要终点为7个月时意向治疗人群的总体缓解率。CT-P10组108例(83%)和利妥昔单抗组104例(81%)达到总体缓解,治疗差异估计值为1.8%(90%CI -6.43至10.20),90%CI在预设的17%等效界值内,显示治疗等效。CT-P10在疗效上与利妥昔单抗等效且耐受性良好,作者建议CT-P10单药可作为低肿瘤负荷滤泡性淋巴瘤患者的新治疗选择。

要点

  • CT-P10组7个月总体缓解率83%(108/130),利妥昔单抗组81%(104/128),治疗差异1.8%(90%CI -6.43至10.20)。
  • 90%CI在预设17%等效界值内,CT-P10与利妥昔单抗疗效等效。
  • CT-P10组6例(5%)和利妥昔单抗组3例(2%)发生至少一次治疗中出现的不良事件。

核心结论

  • CT-P10在疗效上与利妥昔单抗等效且耐受性良好。
  • 作者建议CT-P10单药可作为低肿瘤负荷滤泡性淋巴瘤患者的新治疗选择。

研究设计与样本

  • 正在进行的随机、双盲、平行组、活性对照3期试验。
  • 纳入年龄≥18岁、II-IV期低肿瘤负荷滤泡性淋巴瘤成人患者,按1:1随机分配至CT-P10或美国来源利妥昔单抗,按地区、分期和年龄分层。
  • 2015年11月9日至2018年1月4日期间评估402例患者资格,258例被随机分配:130例至CT-P10组,128例至利妥昔单抗组。
  • 治疗方案:CT-P10或利妥昔单抗375 mg/m2静脉给药,诱导期为4个7天周期中的第1天给药;诱导期后有疾病控制者继续维持治疗,每8周一次共6周期,若完成则提供第二年维持治疗(额外CT-P10每8周一次共6周期)。
  • 数据库锁定(2018年2月23日)后对截至7个月(维持期第3周期前)的所有数据部分揭盲;主要终点为意向治疗人群7个月时达到总体缓解的患者比例;若CT-P10与利妥昔单抗缓解比例的治疗差异双侧90%CI在17%等效界值内则显示疗效等效。

主要发现

  • CT-P10组108/130例(83%)和利妥昔单抗组104/128例(81%)在7个月时达到总体缓解,治疗差异估计值为1.8%(90%CI -6.43至10.20)。
  • 治疗等效性成立(90%CI在预设17%界值内)。
  • 最常见的3级或4级治疗中出现的不良事件为中性粒细胞计数降低(CT-P10组2例3级)和中性粒细胞减少(每组各1例);所有其他3级或4级治疗中出现的不良事件各发生于1例患者。
  • CT-P10组6/130例(5%)和利妥昔单抗组3/128例(2%)经历至少一次治疗中出现的严重不良事件。

关键数值与推荐

  • 主要终点:7个月时意向治疗人群总体缓解比例,CT-P10组83%(108/130)vs 利妥昔单抗组81%(104/128),治疗差异估计值1.8%(90%CI -6.43至10.20)。
  • 等效界值:治疗差异双侧90%CI在17%内即显示疗效等效。
  • 3级或4级治疗中出现的不良事件:中性粒细胞计数降低(CT-P10组2例3级)、中性粒细胞减少(每组各1例)。
  • 治疗中出现的严重不良事件:CT-P10组6/130例(5%)vs 利妥昔单抗组3/128例(2%)。

临床怎么用

  • 作者建议CT-P10单药可作为低肿瘤负荷滤泡性淋巴瘤患者的新治疗选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies in patients with rheumatoid arthritis and advanced follicular lymphoma have shown that CT-P10, a rituximab biosimilar, has equivalent or non-inferior efficacy and pharmacokinetics to rituximab. We aimed to assess the therapeutic equivalence of single-agent CT-P10 and rituximab in patients with newly diagnosed low-tumour burden follicular lymphoma. METHODS: In this ongoing, randomised, double-blind, parallel-group, active-controlled, phase 3 trial, adult patients (≥18 years) with stage II-IV low-tumour-burden follicular lymphoma were randomly assigned (1:1) using an interactive web or voice response system stratified by region, stage, and age to CT-P10 or US-sourced rituximab. Patients received CT-P10 or rituximab (375 mg/m2 intravenous) on day 1 of four 7-day cycles (induction period). Patients who had disease control after the induction period continued to a maintenance period of CT-P10 or rituximab administered every 8 weeks for six cycles and, if completed, a second year of maintenance therapy of additional CT-P10 (every 8 weeks for six cycles) was offered. The study was partially unmasked after database lock (Feb 23, 2018) for all data up to 7 months (before cycle 3 of the maintenance period). The primary endpoint was the proportion of patients who achieved an overall response by 7 months in the intention-to-treat population. Efficacy equivalence was shown if the two-sided 90% CIs for the treatment difference in the proportion of responders between CT-P10 and rituximab was within the equivalence margin of 17%. This trial is registered with ClinicalTrials.gov, number NCT02260804. FINDINGS: Between Nov 9, 2015, and Jan 4, 2018, 402 patients were assessed for eligibility, of whom 258 were randomly assigned: 130 to CT-P10 and 128 to rituximab. 108 (83%) of 130 patients assigned to CT-P10 and 104 (81%) of 128 assigned to rituximab achieved an overall response by month 7 (treatment difference estimate 1·8%; 90% CI -6·43 to 10·20). Therapeutic equivalence was shown (90% CIs were within the prespecified margin of 17%). The most common grade 3 or 4 treatment-emergent adverse events were decreased neutrophil count (two grade 3 in the CT-P10 group) and neutropenia (one in each group); all other grade 3 or 4 treatment-emergent adverse events occurred in one patient each. Six (5%) of 130 patients who received CT-P10 and three (2%) of 128 who received rituximab experienced at least one treatment-emergent serious adverse event. INTERPRETATION: CT-P10 was equivalent to rituximab in terms of efficacy and was well tolerated. CT-P10 monotherapy is suggested as a new therapeutic option for patients with low-tumour-burden follicular lymphoma. FUNDING: Celltrion, Inc.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Ogura M, Sancho JM, Cho SG, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. Lancet Haematol. 2018. PMID: 30389036. doi:10.1016/S2352-3026(18)30157-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。